Abstracts

1. Ts'o¹, POP, Lesko¹, SA, Lum¹, ZP, Deamond¹, S, Shan¹, E, Zhou¹, D, Daniel¹, JR, Van Echo¹, D, Tkaczuk², K, Tait², NS, Feldman², F, Edelman², MJ, Suntharalingam², M, Tan², M, Rodgers², W. Drug Response Indicators Test (DRIT) for personalized anticancer chemotherapy for late stage breast cancer (BC) and non-small cell lung cancer (NSCLC) patients.The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 22-26, 2007, San Francisco, CA. 1: CCC Diagnostics, LLC, Baltimore, MD, 2: University of Maryland Greenebaum Cancer Center, Baltimore, MD.

2. Tkaczuk ¹, KHR, Tait¹, NS, Rodgers², WH, Tan³,M, Ioffe², O, Lesko⁴, SA, Deamond⁴,S, Lum⁴, ZP, Ts'o⁴, POP. Clinical Studies Correlating Patients' Responses To Anticancer Drugs With The Level Of Expression Of Drug Response Indicators (Dri) Measured In The Patient's Tumor Tissue. The 4th Congress of the World Society for Breast Health Meeting, Tianjin, China, October 18-21, 2007. 1: University of Maryland Departments of Oncology; 2: Pathology; 3: Biostatistics; 4: CCC Diagnostics LLC, Baltimore, MD.

3. Ts'o¹, POP, Lesko¹, SA, Lum¹, ZP, Deamond¹, S, Shan¹, E, Zhou¹, D, Daniel¹, JR, Van Echo¹, D, Tkaczuk², K, Tait², NS, Tan², M, Ioffe², O, Rodgers², W. Drug Response Indicators Test (DRIT) for personalized anticancer chemotherapy for stage IV breast cancer (BC) patients. AACR Breast Cancer Conference, October 17-20, 2007, San Diego, CA. Poster. 1: CCC Diagnostics, LLC, Baltimore, MD, 2: University of Maryland Greenebaum Cancer Center, Baltimore, MD.

4. Edelman, MJ, Kwong, K, Suntharalingam, M, Tan, M, Rodgers, W, Lesko, S, Ts'o,POP.ERCC1 and Beta Tubulin III (BTUB) Isoform Expression by Immunofluorescence (IF) May Correlate with Survival after Combined Modality Therapy (CMT) for Stage III NSCLC.International Association for the Study of Lung Cancer, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

5. Tkaczuk, KA, Van Echo, DA, Tait, N, Feldman, F, Lum, ZP, Lesko, S, Ts'o, POP;University of Maryland Greenebaum Cancer Center, Baltimore, MD/CCC Diagnostics, Baltimore, MD. Circulating Cancer Cells in Breast Cancer Patients. 2005 ASCO Meeting. http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-002001,00.asp

6. Ts'o, POP, Lesko, SA, Lum, ZP, Deamond, SF, Shan, E, Zhou, DB, Daniel JR. Personalized anticancer chemotherapy based on the measurement of drug response indicators (DRI) expressed by cancer cells. AACC 37th Oakridge meeting, Abstract # 32, April 2005, Baltimore, MD.

7. Edelman, MJ, Bisaccia, S, Smith, R, Lesko, SA, Lum, ZP, Ts'o, POP; University of Maryland Greenebaum Cancer Center, Baltimore, MD/CCC Diagnostics, Baltimore, MD. Circulating cancer cells (CCC) in non-small cell lung cancer (NSCLC): incidence and preliminary observations on prognostic significance and potential for individualized therapy. 2005 ASCO Meeting. Circulating cancer cells (CCC) in non-small cell lung cancer-2005 ASCO

8. Ts'o, POP, Lesko, SA, Lum, ZP , Deamond, SF, Shan, E, Zhou, DB, Daniel, JR, CCC Diagnostics, LLC, Baltimore, MD. Drug Response Indicators in Cancer Cells Provide the Basis of Personalized Anticancer Chemotherapy. 7th Annual NIH SBIR/STTR Conference July 2005.

9. Ts'o, POP, Lesko, SA, Lum, ZP, Deamond, SF, Shan, E, Zhou, DB , Daniel, JR, Tkaczuk, KH, Tait, NS, Feldman, F, Van Echo DA, CCC Diagnostics, LLC, University of Maryland Greenebaum Cancer Center, Harbor View Cancer Center, Baltimore, Maryland. Drug response indicators in cancer cells provide the bases of personalized anticancer chemotherapy (PAC) for breast cancer (BC). AACR Conference, September 2005, La Jolla, California.